Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
7 November 2016

ORYZON Announces Exercise of Warrants by Alzheimer’s Drug Discovery Foundation (ADDF)

26 October 2016

ORYZON Genomics to Present at Stifel 2016 Healthcare Conference

24 October 2016

ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016

15-16 November 2016

Stifel 2016 Healthcare Conference

Lotte New York Palace Hotel

NY

United States

29 September 2016

ORYZON AT BIOSPAIN 2016

26 September 2016

ORYZON Closes € 5.3 Million (6 M USD) in additional Debt Financing

12 September 2016

Oryzon to Present ORY-2001 Preclinical efficacy data in Multiple Sclerosis animal model at ECTRIMS-2016 Annual Meeting

14 September 2016

ORYZON Selected as one of the Finalist for the 7th Annual Most Innovative EU Biotech SME Award

1 September 2016

Oryzon Genomics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and at BioPharm America 2016

27 July 2016

Oryzon Initiates Multiple Ascending Dose Cohorts In ORY-2001 Phase 1 Clinical Trial

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 43
  • Page 44
  • Page 45
  • Page 46
  • Current page 47
  • Page 48
  • Page 49
  • Page 50
  • Page 51
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel